Agger Mette Kirstine 4
4 · Lexeo Therapeutics, Inc. · Filed Jun 29, 2026
Research Summary
AI-generated summary of this filing
Lexeo (LXEO) Director Mette Agger Receives 35,000-Share Award
What Happened
- Agger Mette Kirstine (listed as a Director) was granted 35,000 derivative securities (reported as an award/acquisition) on 2026-06-25. The filing reports $0.00 paid for the award (no cash transaction reported). This is a grant of convertible/derivative compensation rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-06-25; Form 4 filed: 2026-06-29 (filed within the SEC’s two-business-day window).
- Amount granted: 35,000 derivative securities; reported price: $0.00; total cash value not reported.
- Shares owned after transaction: not specified in this filing.
- Footnote: 100% of the shares underlying the option will vest and become exercisable on the earlier of one year after the grant date or the next annual meeting of stockholders, subject to continuous service.
- Transaction type: Award/Grant (code A); derivative security (option-like award).
Context
- This appears to be a standard equity compensation grant to a director intended for retention/compensation. It is not an immediate purchase or sale of common stock and does not by itself indicate a buy/sell signal. Exercise terms (exercise price, post-vesting disposition) and eventual value will depend on additional plan details not included in this Form 4.
Insider Transaction Report
Form 4
Agger Mette Kirstine
Director
Transactions
- Award
Stock Option (right to buy)
[F1]2026-06-25+35,000→ 35,000 totalExercise: $4.70Exp: 2036-06-24→ Common Stock (35,000 underlying)
Footnotes (1)
- [F1]100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date.
Signature
/s/ Youjin Choi, Attorney-in-Fact|2026-06-29